What are the infection risks of Icotyde (icotrokinra) and how should they be screened, monitored, and managed?

Infection Risk with Icotyde (Icotrokinra)

Icotyde carries a low but measurable infection risk that requires pre-treatment screening for tuberculosis, completion of age-appropriate vaccinations, and avoidance of live vaccines during therapy, with close monitoring for any clinically important infections during treatment. 1

Infection Risk Profile

The infection risk with Icotyde is reassuringly low based on clinical trial data:

• Serious infections: 0.2% with Icotyde vs 0.4% with placebo through 16 weeks 1
• Overall adverse events: 49% in both Icotyde and placebo groups through week 16 1
• Most common infections: Nasopharyngitis and upper respiratory tract infection 1, 2
• Fungal infections: Reported in <1% of patients, including tinea pedis, oral candidiasis, and onychomycosis 1

Through 1 year of treatment (2,400 patients, 1,840 patient-years):

• Infection rate: 76 events per 100 patient-years
• Serious adverse events: 4.6 per 100 patient-years
• Discontinuation due to adverse events: 3.0 per 100 patient-years 3

The safety profile remained consistent through 52 weeks with no concerning signals for opportunistic infections 3.

Pre-Treatment Screening

Tuberculosis Evaluation

Consider TB screening prior to initiating Icotyde based on clinical judgment 1. This is particularly important for:

• Patients from high-incidence TB countries
• Recent TB exposure
• Healthcare workers
• Residents/employees of homeless shelters or correctional facilities 4

For patients with past history of latent or active TB where adequate treatment cannot be confirmed, consider anti-TB therapy before starting Icotyde 1.

Vaccination Requirements

Complete all age-appropriate vaccinations according to current immunization guidelines BEFORE starting Icotyde 1. This includes:

• Pneumococcal vaccine
• Influenza vaccine
• Herpes zoster vaccine (if age-appropriate)
• COVID-19 vaccination 5

Avoid live vaccines during Icotyde treatment as medications that interact with the immune system may increase infection risk following live vaccine administration 1.

Monitoring During Treatment

Active Infection Management

Avoid treatment with Icotyde in patients with any clinically important active infection until the infection resolves or is adequately treated 1.

For patients with chronic infection or history of recurrent infection:

• Carefully weigh risks and benefits before prescribing
• Consider the patient's overall immune status
• Evaluate for underlying immunodeficiency

Ongoing Surveillance

Monitor patients for signs and symptoms of active TB during and after Icotyde treatment 1. Specifically watch for:

• Persistent cough
• Fever
• Night sweats
• Unexplained weight loss

Instruct patients to seek medical advice immediately if signs or symptoms of clinically important infection occur 1.

Management of Breakthrough Infections

If a patient develops a clinically important infection:

1. Monitor the patient closely
2. If not responding to standard therapy, discontinue Icotyde until the infection resolves 1
3. Provide appropriate antimicrobial therapy based on the specific pathogen
4. Consider resuming Icotyde only after complete resolution and adequate treatment

Special Considerations for Fungal Infections

While fungal infections were uncommon (<1%), they included:

• Superficial infections (tinea pedis, tinea versicolor)
• Mucosal candidiasis (oral, vulvovaginal)
• Onychomycosis 1

These infections were generally mild and manageable with standard antifungal therapy without requiring Icotyde discontinuation in most cases.

Risk Stratification

Low-risk patients (appropriate for Icotyde):

• No active infections
• Completed vaccinations
• No history of recurrent serious infections
• Negative or adequately treated TB

Higher-risk patients (require careful consideration):

• Chronic infections
• History of recurrent infections
• Untreated latent TB
• Significant immunosuppression from other causes
• Concurrent immunosuppressive therapy 6

Key Clinical Pitfalls to Avoid

1. Do not start Icotyde in patients with active TB 1
2. Do not administer live vaccines during treatment 1
3. Do not ignore signs of infection - early recognition and treatment are critical
4. Do not continue Icotyde if a serious infection develops and is not responding to standard therapy 1

Comparative Context

The infection risk with Icotyde appears favorable compared to other immunosuppressive therapies:

• Lower infection rates than combination immunosuppression (thiopurines + steroids + anti-TNF) 6
• Similar safety profile to placebo through 16 weeks 1
• Comparable or better than deucravacitinib through 24 weeks (81 vs 119 infections per 100 patient-years) 3

This favorable profile likely reflects Icotyde's selective IL-23 receptor blockade, which provides targeted immunomodulation without broad immunosuppression 2, 7.